Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.2700 (-2.77%) ($5.1100 - $5.4000) on Mon. Oct. 8, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.4% (three month average) | RSI | 22 | Latest Price | $5.2700(-2.77%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -24.3% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) SHY(7%) XHB(6%) DIA(5%) TLT(5%) IPO(4%) | Factors Impacting TGTX price | TGTX will decline at least -3.2% in a week (0% probabilities). XLC(-8%) URA(-8%) ICLN(-7%) BLOK(-7%) XLRE(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.2% (StdDev 6.4%) | Hourly BBV | 0 () | Intraday Trend | -1.5% | | | |
|
1 - 5 Day Possible Target | $-43.98(-934.54%) | Resistance Level | $7.54 | 5 Day Moving Average | $5.39(-2.23%) | 10 Day Moving Average | $5.41(-2.59%) | 20 Day Moving Average | $7.54(-30.11%) | To recent high | -62.4% | To recent low | 2.3% | Market Cap | $667m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |